Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

NACompletedINTERVENTIONAL
Enrollment

1,475

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
SARS-CoV-2 Infection
Interventions
DIETARY_SUPPLEMENT

Vitamin D3

Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.

Trial Locations (2)

60612

Rush University Medical Center, Chicago

60637-1622

University of Chicago, Chicago

All Listed Sponsors
collaborator

Rush University Medical Center

OTHER

lead

University of Chicago

OTHER

NCT04868903 - Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19 | Biotech Hunter | Biotech Hunter